hESC-derived Cardiomyocytes

Human Embryonic Stem Cell derived cardiomyocytes

$500.00$16,000.00
  • Quantity : 2 million to 1 billion cells
  • Shelf life : 1 Year
  • Store at : 4 C

Human Embryonic Stem Cell derived cardiomyocytes

hESC-derived Cardiomyocytes

$500.00$16,000.00

Human Embryonic Stem Cell derived cardiomyocytes

Clear

Overview

Human cardiomyocytes differentiated from pluripotent stem cells are being used extensively in place of animal derived or donor harvested cardiomyocytes. They provide a more consistent and stable source of cells from established cell lines that have been used extensively in research labs. Brilliant research now provides cardiomyocytes made with Genea Biocells’ human embryonic stem cell line, GN19. By applying microcarrier technology, we can generate 100s of million to billions of cardiomyocytes for toxicology testing and tissue engineering and transplantation applications without researchers having to worry about producing the cardiomyocytes themselves [1,2,3]. Brilliant Research can provide quantities ranging from 2 million to 100 million cells at competitive prices because of the very high yields generated by our proprietary technology. Cells can be delivered as a monolayer on microtiter plates or as cell microcarrier aggregates and transported at room temperate for easier shipping and replated on arrival. Larger quantities of 1 billion cells or more, can be custom produced.

Brilliant Research Cardiomyocytes

Fig. 1 Cardiomyocytes stained with sarcomeric actinin (SA), myosin light chain (MLC) and cardiac troponin (cTnT).

 

This product is for research use only and not for use in clinical applications.

Applications

  1. Electrophysiology of ventricular, atrial and pacemaker cardiomyocytes, e.g. patch clamp or multi-electrode arrays [3]. Typically 2 million cells are required.
  2. Toxicology, e.g. testing of chemical drugs, biologics or combination drugs on lengthening or shortening of the QT-interval duration, change in beating frequency and viability of the cardiomyocytes [1,2]. Typically 2 million cells are required.
  3. Formation of cell sheets, either single or multilayers of cardiomyocyte sheets. Typically 10 to 100 million cells are needed per sheet.
  4. Tissue engineering, e.g. injection of cardiomyocytes into decellularised heart tissues of pigs [4]. Typically 100 million cells are required per construct.

Fig. 2 Dose-dependent effect of E-4031 and verapamil on duration of the QT interval of differentiated cardiomyocytes.

Videos

Beating cardiomyocytes

Publications

  1. Lam AT et al. ‘Conjoint propagation and differentiation of human embryonic stem cells to cardiomyocytes in a defined microcarrier spinner culture’. Stem Cell Res Ther. 2014 Sep 15;5(5):110.
  2. Ting S et al. ‘An intermittent rocking platform for integrated expansion and differentiation of human pluripotent stem cells to cardiomyocytes in suspended microcarrier cultures’. Stem Cell Res. 2014 Sep;13(2):202-13.
  3. Laco et al. ‘Cardiomyocyte differentiation of pluripotent stem cells with SB203580 analogues correlates with Wnt pathway CK1 inhibition independent of p38 MAPK signaling’. Journal of Molecular and Cellular Cardiology, 2014 Dec 19;80C:56-70.
  4. Sarig U et al. ‘Pushing the envelope in tissue engineering: ex vivo production of thick vascularized cardiac ECM constructs’. Tissue Eng. Part A 2015 May;21(9-10):1507-19.